Theravance Biopharma Engages Investors at Upcoming BioConnect Conference in NYC
Theravance Biopharma Engages Investors at Upcoming BioConnect Conference in NYC
Theravance Biopharma, Inc. is poised to make a significant impression at the H.C. Wainwright 3rd Annual BioConnect Investor Conference taking place in New York City. Scheduled for May 20, 2025, at 10:30 AM EDT, the company will be featured in a Fireside Chat, introducing its groundbreaking work in the biopharmaceutical sector. This event serves as an integral platform for Theravance to connect with the investment community, sharing insights into its growth trajectory and innovative therapies.
During the conference, Theravance will provide an opportunity for in-person meetings, allowing stakeholders and potential investors to engage directly with company representatives. This format aims to foster a deeper understanding of the company’s ambitions and the valuable impact of its research and developments.
Access to the Fireside Chat will be available via webcast on Theravance’s official website under the Investors section, particularly in the Events and Presentations area. For those unable to attend live, the recording will be archived and accessible for 30 days post-event, ensuring that the insights shared can be revisited and analyzed.
Company Overview
Theravance Biopharma focuses on creating Medicines that Make a Difference® in patients’ lives. The company’s hallmark product, YUPELRI® (revefenacin), is an FDA-approved inhalation solution designed for the maintenance treatment of chronic obstructive pulmonary disease (COPD). This therapy underscores Theravance's commitment to addressing prevalent health issues through effective and carefully developed pharmaceutical solutions.
In addition to YUPELRI, Theravance is also advancing Ampreloxetine, a late-stage investigational drug aimed at treating symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). This treatment has the potential to become a first-in-class therapy, effectively addressing the diverse symptoms experienced by MSA patients. These innovations are a testament to the company’s dedication to enhancing patient care and establishing shareholder value.
With a clear focus on innovation and patient-centered solutions, Theravance Biopharma continues to expand its footprint in the biopharmaceutical landscape. The upcoming conference provides an ideal setting for the company to showcase its achievements and future directions.
For those following Theravance Biopharma and interested in their strategy, innovation, and performance in the biopharmaceutical arena, the BioConnect Investor Conference represents a vital opportunity to gain insights directly from company leaders. Theravance invites all interested parties to participate, engage, and explore the possibilities that lie ahead in its growth and development narrative.
In summary, as Theravance Biopharma prepares for this impactful conference, the anticipation builds around its presentations and the future it envisions not only for its therapies but for the countless lives they aim to improve. For further information regarding the event, and for access to the replay of the webcast, please visit Theravance's official website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.